ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc (EIGR)

1.725
0.00
( 0.00% )
Updated: 20:00:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.725
Bid
1.72
Ask
1.73
Volume
-
0.00 Day's Range 0.00
1.10 52 Week Range 28.50
Previous Close
1.725
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

EIGR Latest News

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger...

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan PR Newswire PALO ALTO...

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split PR Newswire PALO ALTO, Calif., Jan. 4, 2024 PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
26-4.305-71.39303482596.038.26721.11323122.06698805CS
52-20.475-92.229729729722.228.51.123894010.18320373CS
156-242.775-99.2944785276244.5300.6391.1447621117.45855193CS
260-327.975-99.4767970883329.7474.61.1388339181.29752398CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
POAIPredictive Oncology Inc
$ 1.88
(75.70%)
131.65M
PBMPsyence Biomedical Ltd
$ 0.635
(62.24%)
64.29M
SLRXSalarius Pharmaceuticals Inc
$ 3.32
(55.14%)
21.68M
VKTXViking Therapeutics Inc
$ 68.89
(36.66%)
10.69M
GSHDGoosehead Insurance Inc
$ 87.36
(32.97%)
649.68k
TWOU2U Inc
$ 1.56
(-62.14%)
3.72M
CTNTCheetah Net Supply Chain Service Inc
$ 0.2842
(-41.04%)
6.22M
EZFLEzFill Holdings Inc
$ 3.81
(-38.80%)
110.61k
KDLYKindly MD Inc
$ 2.04
(-36.65%)
595.51k
SLGLSol Gel Technologies Ltd
$ 0.4541
(-32.22%)
13.11M
NVDANVIDIA Corporation
$ 113.34
(-0.80%)
265.1M
SQQQProShares UltraPro Short QQQ
$ 9.1003
(0.44%)
144.01M
SLNASelina Hospitality PLC
$ 0.039
(-14.66%)
143.42M
POAIPredictive Oncology Inc
$ 1.88
(75.70%)
143.17M
PBMPsyence Biomedical Ltd
$ 0.635
(62.24%)
69.79M

EIGR Discussion

View Posts
Renee Renee 3 months ago
EIGR changed to EIGRQ, bankruptcy. Delisted from the Nasdaq to the OTC: ***PPS at $1.72 in after hours.

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
2020trader 2020trader 3 months ago
down 10% today, expecting lower
👍️0
2020trader 2020trader 4 months ago
down 4% today
👍️0
2020trader 2020trader 4 months ago
expecting lower
👍️0
Awl416 Awl416 4 months ago
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
👍️0
Awl416 Awl416 4 months ago
Uh oh
👍️0
Disquisition Disquisition 7 months ago
INDEFATIGABLE DUMPING
👍️0
glenn1919 glenn1919 9 months ago
EIGR............................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 10 months ago
EIGR.......................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 months ago
EIGR new 52 week low
👍️0
Triple nickle Triple nickle 1 year ago
Hmmm
👍️0
Disquisition Disquisition 2 years ago
HORRENDOUS DUMPING
👍️0
make it happen make it happen 2 years ago
$50,000,000 share offering. This is adding approximately 1/6 the structure. Decent dilution still not enough to keep the doors open for a year.
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
lol
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
Nice analysis
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
lmao
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
monster rare drug play
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
very nice push coming....rare disease drugs are expensive!!
👍️0
make it happen make it happen 2 years ago
Literally losing over $440,000,000 million a year with only 3.4 mil revenue... Covid is a semi thing of the past now. This has potential to do a reverse split again imho in a year or 2. Not bashing but financials can't add up like this. Hi I'm spending half a Billion dollars a year and have basically zero revenue. Where's this going to come from to keep it going?
👍️0
make it happen make it happen 2 years ago
Volume is not sustainable imo and did a 15 to 1 Reverse split. They don't even have enough cash to cover 1 quarter. Was $0.86
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
watch and learn loser
👍️0
make it happen make it happen 2 years ago
Mid tripple digit negative profitability over 600% NEGATIVE. I don't think I have ever seen such big negative numbers on any ticker my entire life. While burning over $110,000,000 million a quarter... with revenues of 3 mil..

Profitability
Profit Margin -279.34%
Operating Margin (ttm) -633.66%

Management Effectiveness
Return on Assets (ttm) -35.62%
Return on Equity (ttm) -40.51%

Income Statement
Revenue (ttm) 12.14M
Revenue Per Share (ttm) 0.36
EBITDA -76.66M
Net Income Avi to Common (ttm) -33.92M
Diluted EPS (ttm) -1.00


Cash Flow Statement
Operating Cash Flow (ttm) -71.34M
Levered Free Cash Flow (ttm) -41.5M
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
EIGR monster
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
massive bio play taking off in pre!
👍️0
ae kusterer ae kusterer 3 years ago
jhpratt@alphavestcapital.com is my email.Please email me insights into eigr.


alphavestcapital.com

MOST IMPORTANT SUMMARY SENTENCES IN THE LANCET ARTICLE:(paraphrased: EIGR’s interferon works better than monoclonal antibodies at reducing covid viral load.Plus, EIGR’s interferon can be administered on an outpatient basis. )"Added value of this study This study shows that a single subcutaneous injection of 180 µg peginterferon lambda has an antiviral effect in outpatients with COVID-19. The decline in viral load was greater with peginterferon lambda treatment than with placebo. The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads, a finding also reported with monoclonal antibody therapies in patients with COVID-19. However, the magnitude of the viral load decline compared with that of placebo was much greater with peginterferon lambda than has been reported with monoclonal antibody therapies to date. Peginterferon lambda was safe and well tolerated in outpatients with mild-to-moderate COVID-19, with a similar side-effect profile to that of placebo and no concerning laboratory adverse events. Implications of all the available evidence No approved therapy exists for outpatients with COVID-19. This study showed that peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the assessment of antiviral agents for patients with COVID-19. Treatment early in the course of disease might prevent clinical deterioration and shorten the duration of viral shedding, which might have an important public health effect by reducing transmission and reducing the duration of self-isolation."
👍️0
Penny chatter Penny chatter 4 years ago
Dead though lol
👍️0
TheFinalCD TheFinalCD 4 years ago
more NEWS https://ih.advfn.com/stock-market/NASDAQ/eiger-biopharmaceuticals-EIGR/stock-news/83743438/eiger-biopharmaceuticals-sells-priority-review-vou
👍️0
Oger Oger 4 years ago
Let’s go over $20...
👍️0
Penny chatter Penny chatter 4 years ago
They say the right things in the conference call it should go bananas. The drug does have covid implications https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19
👍️0
Oger Oger 4 years ago
You think this rocks tomorrow penny chatter?
👍️0
Penny chatter Penny chatter 4 years ago
Think someone will be stated it. I looked and couldn't find it
👍️0
Oger Oger 4 years ago
Who’s the buyer?
I couldn’t find it...
👍️0
Penny chatter Penny chatter 4 years ago
Folks miss the covid implications here and they already have a buyer here https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19
👍️0
Oger Oger 4 years ago
It will sink it the magnitude of this drug, extending the life of these
children 2-1/2 years ....
👍️0
Penny chatter Penny chatter 4 years ago
I agree as it has 80% institutional ownership
👍️0
Oger Oger 4 years ago
Over $20 on Monday......
👍️0
Penny chatter Penny chatter 4 years ago
They didn't have to halt for this lol
👍️0
TheFinalCD TheFinalCD 4 years ago
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies

https://medlineplus.gov/genetics/condition/hutchinson-gilford-progeria-syndrome/

Progeria
Also known as: hutchinson-gilford progeria syndrome
OVERVIEW
SYMPTOMS
DIAGNOSIS
TREATMENT
A progressive genetic disorder where symptoms of aging are manifested at an early age.
How common is condition?
Extremely rare (Fewer than 1,000 cases per year in US)
Is condition treatable?
Treatments can help manage condition, no known cure
Does diagnosis require lab test or imaging?
Requires lab test or imaging
Condition Highlight
Present at birth, onset can be infantile or juvenile
Condition Highlight
May be dangerous or life threatening
Condition Highlight
Family history may increase likelihood
👍️0
Penny chatter Penny chatter 4 years ago
What kind of fda approval don't see interest?
👍️0
Penny chatter Penny chatter 4 years ago
On it
👍️0
TheFinalCD TheFinalCD 4 years ago
HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ
T1
👍️0
Fezziwig2008 Fezziwig2008 4 years ago
EIGR - Lambda is most paradoxical interferon :
“ IFN-lambda responses to dsRNA in the human infant airway epithelium are regulated by p38-MAPK and NF-kB signaling. High in vivo IFN-lambda production is influenced by virus type and associated with recurrent respiratory sick visits in young children.”


https://scholar.google.com.hk/scholar?start=50&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DpIKe3q7igMIJ
👍️0
MWM MWM 4 years ago
A mutual friend we have really likes it.

Small share structure is compelling...
👍️0
Fezziwig2008 Fezziwig2008 4 years ago
EIGR is expected to release interim data from its Stanford Lambda Trial - I’m not too excited, given the emergent need for any slightly positive data regarding the treatment of SARS2 -see Remdesivir 4 day advantage- and the failure of the data monitoring committee - who already had their interim look/- to halt the study on efficacy - a little bird told me (when I was a vocal advocate of EIGR on Twitter)- that the data was less than compelling to that point weeks ago - certainly that might have changed. The recent insider buy certainly makes on hopeful that it has. A recent seeking alpha pump suggests the upcoming Progeria approval carries tge rest of the pipeline - have you seen how rare Progeria is?
👍️0
MWM MWM 4 years ago
https://seekingalpha.com/instablog/52316800-friar-tuck-esq/5480909-eiger-biopharmaceuticals-low-risk-biotech-10-bagger-near-term-catalyst
👍️0
MWM MWM 4 years ago
$EIGR what is Cooking?

👍️0
MWM MWM 4 years ago
EIGR is cooking...

👍️0
Fezziwig2008 Fezziwig2008 4 years ago
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.”
https://www.frontiersin.org/articles/10.3389/fneur.2020.00146/full
👍️0
Fezziwig2008 Fezziwig2008 4 years ago
On EIGR (Lambda is IFN III) “Treatment with type I and III IFNs can dramatically inhibit SARS-CoV-2 replication in primary human airway epithelial cells with the corresponding induction of ISGs.22 The role of type III IFNs in the suppression of virus replication has been highlighted.23,24 Type III IFN shows a better treatment option than type I IFN for influenza A virus-induced disease for its induction of antiviral immunity without the pro-inflammatory responses.”


https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1.full.pdf
👍️0
Fezziwig2008 Fezziwig2008 4 years ago
EIGR “IFN-Lambda4 showed a strong therapeutic effect in reducing MERS-CoV infection with higher induction of IFN-stimulated genes. Thus, IFN-? has a decisive function in the respiratory epithelium that greatly limits MERS-CoV replication, and may be a key cytokine for better therapeutic outcomes against MERS-CoV infection in respiratory tract.” Success w/1 coronavirus is Promising-awaiting word from Stanford on interim dat in SARS-2 by summer’s end.

https://scholar.google.com/scholar?start=10&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DG9p7gPGYVVwJ
👍️0

Your Recent History

Delayed Upgrade Clock